In healthcare, interest is common. Purchase is rare. The difference is proof.
Early-stage conversations are often driven by novelty and perceived potential. Later-stage decisions are driven by risk reduction. Buyers need to know: will this work here, with our constraints, and will it create value worth paying for?
As you scale, the proof expectations typically shift:
Interest stage:
You can attract attention with a clear problem, a prototype, and a plausible claim.
Pilot stage:
You need evidence of feasibility in a real setting, including usability under real constraints.
Purchase stage:
You need decision-grade outcomes: measurable impact, operational fit, and a credible implementation plan. You also need clarity on what resources the buyer must commit and what they will get in return.
This is why many “successful pilots” do not convert. They produce positive feedback, but not the specific evidence required for a purchase decision. The pilot did not answer the buyer’s risk questions.
A good scaling pathway treats evidence as a go-to-market asset. You do not collect data “because it is nice”. You collect data that directly supports the next decision.
Worthmed® supports this by designing pilots with a clear conversion target, using baseline data analysis to define realistic outcomes, and packaging results into a simple, buyer-friendly evidence narrative.